Controlled human infection modeling and adaptive clinical trial design have the potential to reduce the odds that late-stage clinical trials will fail, says SGS Life Sciences Scientific Director Adrian Wildfire. Adaptive design enables researchers to follow clues and adjust to early findings, but adaptive design might not be needed in trials with simple endpoints, says Wildfire, who adds that researchers should thoroughly analyze preclinical data before designing later trial stages.
Preclinical data, simple endpoints, adaptive design boost trial success odds
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.